Antigens Patents (Class 435/69.3)
  • Production of papillomavirus capsid protein and virus-like particles
    Patent number: 8062642
    Abstract: The present invention is directed to a method of expressing the papillomavirus capsid protein coding sequence in a cell using an expression system under conditions facilitating expression of the protein in the cell. In another aspect of the invention, it has been discovered that virus-like particle(s) (VLPs), fragment(s), capsomer(s) or portion(s) thereof are formed from the papillomavirus capsid protein. It was further discovered that the virus-like particle(s) comprises antigenic characteristics similar to those of native infectious papillomavirus particles. In an embodiment of the invention, there is provided a method of expressing the L1 major capsid protein of human papillomavirus type-11 (HPV-11) in Sf-9 insect cells using the baculovirus expression system, and the production of HPV-11 virus-like particles.
    Type: Grant
    Filed: March 9, 1993
    Date of Patent: November 22, 2011
    Assignee: University of Rochester
    Inventors: Robert Rose, William Bonnez, Richard Reichman
  • PREPARATION METHOD OF RECOMBINANT PROTEIN BY USE OF A FUSION EXPRESSION PARTNER
    Publication number: 20110281300
    Abstract: The present invention relates to a preparation method using a fusion expression partner. The method includes preparing a polynucleotide encoding a fusion expression partner selected from the group consisting of SlyD (FKBR-type peptidyl prolyl cis-trans isomerase), Crr (glucose-specific phosphotransferase (PTS) enzyme IIA component), RpoS (RNA polymerase sigma factor), PotD (Spermidine/putrescine-binding periplasmic protein), and RpoA (RNA polymerase alpha subunit), and an expression vector linking a polyDNA fragment of a heterologous protein, preparing a transformant by introducing the expression vector into a host cell, inducing the expression of a recombinant protein by culturing a transformant, and obtaining the expression.
    Type: Application
    Filed: May 16, 2011
    Publication date: November 17, 2011
    Applicant: Nutrex Technology Co., Ltd
    Inventors: Jeewon Lee, Kyung-Yeon Han, Jong-Am Song, Jin-Seung Park, Hyuk-Seong Seo, Keum-Young Ahn, Eun-Jung Lee, Jong-Hwan Lee, Soo-Jung Kwon
  • HLA-G POLYPEPTIDES AND PHARMACEUTICAL USES THEREOF
    Publication number: 20110274711
    Abstract: The present invention relates to novel proteins and pharmaceutical uses thereof The invention more specifically relates to novel proteins comprising the sequence of an HLA-5 antigen fused to the sequence of a b2 microglobulin. The invention also relates to methods of producing such polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating various diseases including organ/tissue rejection.
    Type: Application
    Filed: November 4, 2009
    Publication date: November 10, 2011
    Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, HLA-G TECHNOLOGIES
    Inventors: Benoit Favier, Edgardo D. Carosella, Joël Lemaoult
  • METHODS FOR ISOLATING ENVELOPED VIRUS-BASED VLPS FREE OF INFECTIOUS AGENTS
    Publication number: 20110262483
    Abstract: Enveloped virus-based virus-like particles (VLPs) that are free of infectious agents and substantially as immunogenic as corresponding VLPs prior to inactivation of infectious agents are described. Improved methods of inactivation infectious agents in preparations of enveloped virus-based VLPs are also described wherein the methods do not adversely affect the immunogenicity of the VLPs.
    Type: Application
    Filed: November 3, 2009
    Publication date: October 27, 2011
    Inventors: Joel R. Haynes, Ross Taylor
  • Chimeric HIV Antigens
    Publication number: 20110262474
    Abstract: The invention provides polynucleotides and polypeptides encoded therefrom that are capable of inducing immune responses to a human immunodeficiency virus. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.
    Type: Application
    Filed: July 23, 2008
    Publication date: October 27, 2011
    Inventors: Xiaohan Du, Li Xu, Robert Whalen, Kristin M. Ostrow
  • DNA REPLICON SYSTEM FOR HIGH-LEVEL RAPID PRODUCTION OF VACCINES AND MONOCLONAL ANTIBODY THERAPEUTICS IN PLANTS
    Publication number: 20110262966
    Abstract: Plant viral vectors have great potential in rapid production of proteins, but no simple. Here a geminivirus-based system for high-yield and rapid production of oligomeric protein complexes, including virus-like particle (VLP) vaccines and monoclonal antibodies (mAbs) is described. In particular, a single vector that contains two non-competing replicons for transient expression in Nicotiana benthamiana leaves is described. The correct assembly of these subunit proteins into functional oligomeric structures (VLPs or full-size mAb) is also described. This system advances plant transient expression technology by eliminating the need for non-competing viruses, and thus, enhances the realistic commercial application of this technology for producing multiple-subunit protein complexes.
    Type: Application
    Filed: August 27, 2009
    Publication date: October 27, 2011
    Applicant: Arizona Board of Regents for and on Behalf of Arizona State University
    Inventors: Hugh S. Mason, Zhong Huang, Qiang Chen, Charles J. Arntzen, Shuo Yuan, Brooke Hjelm
  • GENES ENCODING MAJOR CAPSID PROTEIN L1 OF HUMAN PAPILLOMA VIRUS
    Publication number: 20110256182
    Abstract: The present invention discloses a codon-optimized gene encoding major capsid protein L1 of human papilloma virus, which is capable, after transduced into a yeast cell, of efficiently expressing the major capsid protein L1 of human papilloma virus. The present invention also discloses an immunogenic macromolecule which is essentially produced by expression of said codon-optimized gene encoding the major capsid protein L1 of human papilloma virus in a yeast cell. The present invention further discloses the use of said immunogenic macromolecule and a composition comprising said immunogenic macromolecule.
    Type: Application
    Filed: November 24, 2008
    Publication date: October 20, 2011
    Inventors: Gaoxia Zhang, Qiong Shen, Jianqiang Lei, Jingyu Yuan, Menghua Zhang, Qianli Zhang, Yinghua Xiong, Roger Wei, Ke Wu
  • MODIFIED GP140 ENVELOPE POLYPEPTIDES OF HIV-1 ISOLATES, COMPOSITIONS, STABILIZED TRIMERIC COMPLEXES, AND USES THEREOF
    Publication number: 20110250220
    Abstract: This invention provides a modified gp140 envelope polypeptide of an HIV-1 isolate comprising a gp120 polypeptide portion comprising consecutive amino acids and a gp41 ectodomain polypeptide portion comprising consecutive amino acids, said gp41 ectodomain polypeptide portion being modified to comprise isoleucine (I) at an amino acid position equivalent to amino acid position 535; glutamine (Q) at an amino acid position equivalent to amino acid position 543; serine (S) at an amino acid position equivalent to amino acid position 553; lysine (K) at an amino acid position equivalent to amino acid position 567; and arginine (R) at an amino acid position equivalent to amino acid position 588, the amino acid positions being numbered by reference to the HIV-1 isolate KNH1144. This invention also provides nucleic acids encoding such a polypeptide, vectors, host cells, trimeric complexes and compositions thereof.
    Type: Application
    Filed: May 4, 2011
    Publication date: October 13, 2011
    Inventors: Antu K. Dey, John P. Moore, William C. Olson, Sai Prasad N. Iyer, Yun (Kenneth) Kang, Michael Franti
  • Surface antigen
    Patent number: 8034358
    Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: October 11, 2011
    Assignee: The University of Queesland
    Inventors: Ian Richard Anselm Peak, Michael Paul Jennings, E. Richard Moxon
  • Flu vaccines and methods of use thereof
    Patent number: 8030029
    Abstract: This disclosure is directed, inter alia, to polynucleotides, polypeptides, vectors, cells and compositions comprising the same, and their use in affecting viral pathogenesis, in particular for influenza viral infection.
    Type: Grant
    Filed: January 23, 2008
    Date of Patent: October 4, 2011
    Assignees: Academia Sinica, The Rockefeller University
    Inventors: David D. Ho, Yaoxing Huang, Ming Wei Chen, Rachel TJ Cheng, Chi-Huey Wong, Alice Yu
  • and genes and uses thereof
    Patent number: 8030471
    Abstract: The subject invention relates to nucleic acid sequences and amino acid sequences encoded thereby, derived from the Merozoite Surface Protein (MSP1) gene of the Plasmodium species P. malariae and P. ovale. Such genes and proteins have many beneficial diagnostic as well as therapeutic uses.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: October 4, 2011
    Assignee: Abbott Laboratories
    Inventors: Larry G. Birkenmeyer, Anthony S. Muerhoff, Suresh M. Desai, George J. Dawson, Bruce J. Dille
  • FOOT AND MOUTH DISEASE VIRUS RECOMBINANT VACCINES AND USES THEREOF
    Publication number: 20110236416
    Abstract: The present invention encompasses FMDV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FMDV antigens. The invention also encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or porcines, against FMDV.
    Type: Application
    Filed: March 11, 2011
    Publication date: September 29, 2011
    Inventors: Jean-Christophe Audonnet, Xuan Guo, Bradley J. Feilmeir, Karolyn Marie Troupe, Michel Bublot, Kevin Cox
  • RESPIRATORY SYNCTIAL VIRUS (RSV) SEQUENCES FOR PROTEIN EXPRESSION AND VACCINES
    Publication number: 20110236408
    Abstract: The invention provides RSV fusion (F) protein ectodomain polypeptide sequences and nucleotide sequences encoding them, as well as cells containing the invention's polypeptide and nucleotide sequences. The invention further provides VLPs that contain the invention's polypeptides, and methods for using the VLPs for protein expression and vaccine formulation. Also provided are methods for distinguishing between subjects immunized with the invention's compositions and subjects infected with RSV.
    Type: Application
    Filed: September 30, 2009
    Publication date: September 29, 2011
    Inventor: Trudy G. Morrison
  • BLUETONGUE VIRUS RECOMBINANT VACCINES AND USES THEREOF
    Publication number: 20110236420
    Abstract: The present invention encompasses BTV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing BTV antigens. The invention also encompasses recombinant vectors encoding and expressing BTV antigens, epitopes or immunogens which can be used to protect animals, such as ovines, bovines, or caprines, against BTV.
    Type: Application
    Filed: March 11, 2011
    Publication date: September 29, 2011
    Inventors: Jean-Christophe Audonnet, Xuan Guo, Kevin Cox
  • Recombinant merozoite surface proteins 4 and 5 and their use
    Patent number: 8026354
    Abstract: Accordingly, the invention provides constructs in which the nucleic acids encoding Plasmodium falciparum MSP4 and MSP5, and the resulting polypeptides, have been modified. More particularly, this invention provides constructs encoding recombinant MSP4 and MSP5 polypeptides, which are expressed as soluble, secreted polypeptides in a baculovirus-insect cell expression system. It was surprisingly found that the recombinant polypeptides contain an EGF-like domain at the C-terminus that is properly folded in the polypeptide.
    Type: Grant
    Filed: November 22, 2006
    Date of Patent: September 27, 2011
    Assignees: Institut Pasteur, Centre Nationale de la Recherche Scientifique
    Inventors: Shirley Longacre, Hannah Polson, Ronald Perraut, Faridabano Nato
  • POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS
    Publication number: 20110229509
    Abstract: Disclosed are polypeptides comprising an amino acid sequence structurally related to SEQ ID NO 1 and uses of such polypeptides and compositions thereof. SEQ ID NO 1 is a full length S. aureus sequence. A derivative of SEQ ID NO 1 containing an amino terminal his-tag was found to produce a protective immune response against S. aureus.
    Type: Application
    Filed: November 18, 2009
    Publication date: September 22, 2011
    Inventors: Tessie B. McNeely, Leslie D. Cope, Mark A. Miller, Loren D. Schultz, Xinmin Wang
  • Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
    Publication number: 20110229504
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: March 18, 2011
    Publication date: September 22, 2011
    Applicant: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens FRITSCHE, Toni WEINSCHENK, Steffen WALTER, Peter LEWANDROWSKI, Harpreet SINGH
  • POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS
    Publication number: 20110229508
    Abstract: The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides and compositions thereof. SEQ ID NO: 1 is a full length S. aureus sequence. A derivative of SEQ ID NO: 1 containing an amino terminus his-tag was found to produce a protective immune response against S. aureus.
    Type: Application
    Filed: November 18, 2009
    Publication date: September 22, 2011
    Inventors: Tessie B. McNeely, Leslie D. Cope, Mark A. Miller, Loren D. Schultz, Xinmin Wang
  • Methods for the diagnosis and treatment of cancer based on AVL9
    Publication number: 20110229505
    Abstract: The present invention relates to methods for the diagnosis and treatment of cancer in mammals, in particular gastric cancer, based on the new target AVL9. The present invention thus relates to diagnostic methods and related components to be used in such methods. Furthermore, the present invention relates to the treatment of cancer in mammals, in particular gastric cancer, based on AVL9 as a target. Specifically, the present invention relates to the immunotherapy of cancer using AVL9 tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides, and respective pharmaceutical compositions, in particular vaccine compositions.
    Type: Application
    Filed: March 18, 2011
    Publication date: September 22, 2011
    Applicant: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens FRITSCHE, Toni WEINSCHENK, Steffen WALTER, Peter LEWANDROWSKI, Harpreet SINGH, Oliver SCHOOR
  • CHIMERIC HEPATITIS C VIRUS ANTIGENS FOR ELICITING AN IMMUNE RESPONSE
    Publication number: 20110223185
    Abstract: Disclosed herein are chimeric antigens, comprising an hepatitis C virus (HCV) antigen and a Fc fragment of an immunoglobulin for eliciting an immune response against said antigen. The immune response is enhanced by presenting the host immune system with an immune response domain (HCV antigen from HVC core, envelope, or non-structural protein fragments) and a target binding domain (an Fc fragment). By virtue of the target binding domain, antigen presenting cells internalize and process the chimeric antigens for antigen presentation, thereby eliciting both a humoral and cellular immune response.
    Type: Application
    Filed: May 18, 2011
    Publication date: September 15, 2011
    Inventors: Rajan George, Lorne Tyrrell, Antoine Noujaim, Dakun Wang, Allan Ma, Bruce Motyka, Bruce Darryl Hirsche
  • Modified HIV-1 envelope proteins
    Patent number: 8017126
    Abstract: The present invention relates to modified HIV-1 envelope proteins which express epitopes that produce a broadly cross reactive neutralizing response, their methods of use and antibodies which bind to these epitopes.
    Type: Grant
    Filed: August 29, 2005
    Date of Patent: September 13, 2011
    Assignees: Henry M. Jackson Foundation for the Advanvement of Military Medicine Inc., Prince Leopoid Institute of Trtopical Medicine
    Inventors: Gerald Quinnan, Fatim Cham, Guido Van Der Groen
  • Chimpanzee Adenovirus Vaccine Carriers
    Publication number: 20110217332
    Abstract: The present invention provides recombinant replication-defective adenoviral vectors derived from chimpanzee adenoviruses and methods for generating recombinant adenoviruses in human E1-expressing cell lines. The invention also provides compositions and methods suitable for use for the delivery and expression of transgenes encoding immunogens against which a boosted immune response is desired. The invention further provides methods of generating clinical grade vector stocks suitable for use in humans. In a particular embodiment the invention contemplates the use of vectors comprising transgenes which encode tumor associated antigens in vaccines and pharmaceutical compositions for the prevention and treatment of cancer.
    Type: Application
    Filed: January 18, 2005
    Publication date: September 8, 2011
    Inventors: Stefano Colloca, Alfredo Nicosia, Elisabetta Sporeno, Paolo Palazzolo, Agostino Cirillo, Bruno Bruni Ercole, Annalisa Meola
  • Papillomavirus vaccines
    Patent number: 8012679
    Abstract: Seven polyclonal and monoclonal antibodies were characterized for their ability to react specifically with either conformational or non-conformational epitopes of the HPV-1 virion. Using these antibodies, it was shown that the HPV-1 L1 protein (when expressed by an SV40 vector in cos cells) displayed conformational epitopes characteristic of intact viral particles. In addition, the L1 capsid protein was translocated normally into cell nuclei, was of appropriate size (57kD), and could be isolated in native form by immunoprecipitation techniques. Most importantly, the screening of expressed papillomavirus capsid proteins for reactivity with conformation-dependent antibodies represents a new, general methodology for ensuring that such proteins will be suitable for use in vaccine development or in the serologic detection/typing of human papillomavirus infections.
    Type: Grant
    Filed: December 16, 1996
    Date of Patent: September 6, 2011
    Assignee: Georgetown University
    Inventors: C. Richard Schlegel, A. Bennett Jenson
  • Universal virus-like particle (VLP) influenza vaccines
    Publication number: 20110212128
    Abstract: Described herein are influenza virus-like particles (VLPs) that display on truncated, re-engineered or remodeled HA molecules on their surface. Also described are methods of making and using these VLPs.
    Type: Application
    Filed: February 18, 2011
    Publication date: September 1, 2011
    Applicant: TechnoVax, Inc.
    Inventors: Jose M. Galarza, George R. Martin
  • Yeast-based therapeutic for chronic hepatitis C infection
    Patent number: 8007816
    Abstract: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.
    Type: Grant
    Filed: August 22, 2008
    Date of Patent: August 30, 2011
    Assignee: GlobeImmune, Inc.
    Inventors: Richard C Duke, Alex Franzusoff, Aurelia Haller, Thomas H King
  • Self-Replicating Vector Lacking An Antibiotic-Resistance Gene
    Publication number: 20110207173
    Abstract: The subject matter of the present invention is a novel vector and the use thereof for producing a heterologous protein or a gene of interest, that can be used, for example, in the context of an immunization or gene therapy programme and concerns in particular a self-replicating vector lacking an antibiotic-resistance gene, comprising a sequence encoding the ccdA protein functionally linked to a first promoter, the sequence of the Cer locus and a heterologous sequence, functionally linked to a second promoter.
    Type: Application
    Filed: July 9, 2009
    Publication date: August 25, 2011
    Applicant: SANOFI PASTEUR S.A.
    Inventors: Regis Sodoyer, Denis Speck, Isabelle Peubez, Nicolas Chaudet
  • Recombinant Expression Vector Elements (REVES) for Enhancing Expression of Recombinant Proteins in Host Cells
    Publication number: 20110201053
    Abstract: Compositions and methods comprising recombinant expression vector elements (rEVEs) to enhance the level of expression of recombinant proteins are described. Other compositions and methods for lowering, substantially suppressing, or essentially silencing expression of a recombinant protein are also described.
    Type: Application
    Filed: April 29, 2011
    Publication date: August 18, 2011
    Inventors: WENDY R. GION, GERALD R. CARSON, HONG GAO, YUNE Z. KUNES
  • Mycobacteria expressing HIV-1 and malaria antigens
    Patent number: 7998471
    Abstract: Provided are recombinant mycobacteria expressing an HIV-1 antigen and a malarial antigen. Also provided are Mycobacterium smegmatis expressing an HIV-1 antigen. Further provided are vaccines capable of inducing an immune response in a mammal against HIV-1 and the malarial pathogen. Additionally provided are methods of inducing an immune response in a mammal against HIV-1 and a malarial pathogen. Also provided are methods of inducing an immune response in a mammal against HIV-1. The methods comprise infecting the mammal with any of the above-described mycobacteria.
    Type: Grant
    Filed: January 11, 2006
    Date of Patent: August 16, 2011
    Assignees: Albert Einstein College of Medicine of Yeshiva University, Beth Israel Deaconess Medical Center, Inc., Duke University
    Inventors: William R. Jacobs, Jr., Norman L. Letvin, Mark Cayabyab, Barton F. Haynes, Hua-Xin Liao, Jae-Sung Yu, Avi-Hai Hovav
  • VIRUS-LIKE PARTICLES COMPRISING COMPOSITE CAPSID AMINO ACID SEQUENCES FOR ENHANCED CROSS REACTIVITY
    Publication number: 20110195113
    Abstract: The present invention provides polypeptides having a composite amino acid sequence derived from a consensus sequence representing the capsid proteins of two or more circulating strains of a non-enveloped virus. In particular, the invention provides virus-like particles comprising at least one composite polypeptide. Such virus-like particles have antigenic epitopes of two or more circulating strains of a non-enveloped virus and produce an increase in antisera cross-reactivity to one or more circulating strains of the non-enveloped virus. Methods of making composite virus-like particles and vaccine formulations comprising composite virus-like particles are also disclosed.
    Type: Application
    Filed: February 8, 2011
    Publication date: August 11, 2011
    Applicant: LigoCyte Pharmaceuticals, Inc.
    Inventors: Charles RICHARDSON, Robert F. Bargatze, Joel Haynes, Bryan Steadman
  • COMPOSITIONS, METHODS, AND KITS FOR ENHANCING THE IMMUNOGENICITY OF PATHOGENIC ANTIGENS
    Publication number: 20110195089
    Abstract: The invention provides a method of enhancing the immunogenicity of pathogenic antigens by removing or disrupting intrachain disulfide bonds responsible for maintaining tertiary protein structure. Removal of one or more disulfide bonds can increase the titer of neutralizing antibodies to a pathogen (e.g., a bacterium, fungus, virus, or parasite). The invention also features vaccines, expression vectors, and methods for the manufacture and use thereof.
    Type: Application
    Filed: October 8, 2009
    Publication date: August 11, 2011
    Applicant: The Adminstrators of the Tulane Educational Fund
    Inventor: Samuel J. Landry
  • Vaccine for avian influenza and methods of use
    Patent number: 7993655
    Abstract: The subject invention pertains to influenza vaccines and particularly avian influenza vaccines (AIV). The invention includes methods for preparing transgenic plant cells to express know HA1 polypeptides having specified homologies that are used to prepare vaccine compositions and methods for inducing protective immunity in an individual, animal, mammal or human.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: August 9, 2011
    Assignee: Dow AgroSciences LLC
    Inventors: Steven Robert Webb, Matthew J. Henry
  • Plasmodium vivax hybrid circumsporozoite protein and vaccine
    Publication number: 20110189218
    Abstract: Described in this application is a synthetic P. vivax circumsporozoite protein useful as a diagnostic reagent, for antibody production, and as a vaccine protective against infection with any strain of P. vivax.
    Type: Application
    Filed: July 9, 2010
    Publication date: August 4, 2011
    Inventors: Anjali Yadava, Christian F. Ockenhouse
  • INFLUENZA VIRUS IMMUNIZING EPITOPE
    Publication number: 20110191915
    Abstract: A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of a novel influenza HA protein in plants and its purification The invention is also directed towards a VLP comprising influenza HA protein and plants lipids. The invention is also directed to a nucleic acid encoding improved influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.
    Type: Application
    Filed: July 15, 2009
    Publication date: August 4, 2011
    Inventors: Manon Couture, Louis-Philippe Vezina, Nathalie Landry
  • Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
    Publication number: 20110189178
    Abstract: The present application relates to therapeutic moieties displaying reduced immunogen response, particularly for therapeutic purposes.
    Type: Application
    Filed: February 4, 2011
    Publication date: August 4, 2011
    Applicant: XENCOR, INC.
    Inventors: John Desjarlais, Gregory L. Moore, Holly M. Horton
  • METAL-CITRATE TRANSPORTER ANTIGEN FROM STREPTOMYCES COELICOLOR AND USES THEREOF
    Publication number: 20110189196
    Abstract: The present invention relates to an isolated antigen from Streptomyces coelicolor that is useful for developing, inter alia, vaccines against pathogenic bacteria of humans and animals. The present invention also relates to vaccines and antibodies developed using the isolated antigen. The present invention also relates to methods of using the antigen, vaccines, and antibodies of the present invention to detect, treat, and prevent infection and diseases associated with pathogenic bacteria.
    Type: Application
    Filed: June 8, 2009
    Publication date: August 4, 2011
    Applicant: SYRACUSE UNIVERSITY TECHNOLOGY TRANSFER AND INDUSTRIAL DEVELOPMENT OFFICE
    Inventors: Robert P. Doyle, Joshua J. Lensbouer
  • Identification of antigens for use in the diagnosis, treatment and monitoring of periodontal diseases
    Patent number: 7981631
    Abstract: Antibodies, polypeptides, and polynucleotides are provided for the detection, prevention, amelioration and treatment of diseases caused by Actinobacillus actinomycetemcomitans.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: July 19, 2011
    Assignee: University of Florida Research Foundation
    Inventors: Martin Handfield, Jeffrey Daniel Hillman, Ann Progulske-Fox
  • EXPRESSION AND ASSEMBLY OF HUMAN GROUP C ROTAVIRUS-LIKE PARTICLES AND USES THEREOF
    Publication number: 20110171316
    Abstract: Group C rotaviruses are a cause of acute gastroenteritis in children and adults that is distinct from group A RV. However, human group C rotaviruses cannot be grown in culture, resulting in a lack of tools for detection and treatment of GrpC RV disease. Consequently, the burden of GpC RV disease has not been clearly established. Isolated recombinant human rotavirus group C virus-like particles are provided according to embodiments of the present invention along with methods of their production and use in, inter alia, detection of Grp C RV infection, diagnostic assays and immunogenic compositions.
    Type: Application
    Filed: May 29, 2009
    Publication date: July 14, 2011
    Applicant: The Government of the US, as represented by the Secretary, Department of Health and Human Services
    Inventor: Baoming Jiang
  • COMPOSITIONS AND METHODS OF USE OF ORF-1358 FROM BETA-HEMOLYTIC STREPTOCOCCAL STRAINS
    Publication number: 20110171263
    Abstract: The present invention relates to polynucleotides encoding Streptococcus group C and G polypeptides and their use in immunogenic compositions. The invention also relates to immunogenic compositions comprising polypeptides encoded by those polynucleotides. In addition, the invention relates to methods of inducing an immune response in mammals against beta hemolytic Streptococcus or beta hemolytic Streptococcus infection using immunogenic compositions of the Streptococcus group C and G polypeptides and polynucleotides.
    Type: Application
    Filed: February 16, 2011
    Publication date: July 14, 2011
    Applicant: Wyeth LLC
    Inventors: Ellen Murphy, Emily Mara Braunstein, Dorys Garcia-Hand, Annaliesa Sybil Anderson, Ingrid Lea Dodge, Eduardo Arturo Rojas
  • PHEP, AN AMINO ACID PERMEASE OF STAPHYLOCOCCUS AUREUS
    Publication number: 20110171237
    Abstract: The present invention relates to antigenic polypeptides expressed by pathogenic microbes, including antigenic polypeptides encoded by the nucleic acid sequence of FIG. 1, vaccines comprising the antigenic polypeptides and therapeutic antibodies directed to the antigenic polypeptides.
    Type: Application
    Filed: April 23, 2010
    Publication date: July 14, 2011
    Applicant: ABSYNTH BIOLOGICS LTD.
    Inventor: Simon J. FOSTER
  • MALARIA VACCINE
    Publication number: 20110171266
    Abstract: The present invention features immunogenic compositions based on pre-fertilization or post-fertilization antigens expressed in the circulating gametocytes in the peripheral blood of infected persons or on the malaria parastes' stages of develop-ment in the mosquito midgut including extracellular male and female gametes, fertilized zygote and ookinete. The invention also features methods to prevent the transmission of malaria using the immunogenic compositions of the invention.
    Type: Application
    Filed: July 22, 2009
    Publication date: July 14, 2011
    Applicants: THE JOHNS HOPKINS UNIVERSITY, The Government of the United States, as represented by the Secretary of the Army
    Inventors: Nirbhay Kumar, Evelina Angov
  • HBV Vaccine and a Process of Preparing the Same
    Publication number: 20110165194
    Abstract: The present invention relates to an HBV vaccine comprising an entire hepatitis B surface antigen of L protein, M protein and S protein, in which the produced antigens form virus-like particles, and a multi-antigen vaccine further comprising an HBV core antigen in addition to the entire surface antigen, and a method for preparing the same. The vaccines provide various epitopes and have excellent immunogenicity to induce a strong humoral immune response as well as a cell-mediated immune response.
    Type: Application
    Filed: January 28, 2008
    Publication date: July 7, 2011
    Inventors: Jung Sun Yum, Byung Cheol Ahn, Hyun Jin Jo, Dong Yeon Kim, Joo Youn Lee, Ki Hyun Kim, Jae Seung Yoon, Hong Mo Moon
  • T24 antigen for immunodiagnosis of cysticercosis
    Patent number: 7972606
    Abstract: The present disclosure relates to T24 nucleic acid sequences, amino acid sequences, and antibodies. Methods for detecting and diagnosing Taenia solium infection in a subject using the T24 sequences and specific binding agents are also disclosed. The T24 sequences disclosed herein can be formulated into a pharmaceutical composition for administration to a subject. For example, the disclosed T24 polypeptides can also be administered to a subject to stimulate an immune response in the subject, thereby protecting the subject against T. solium infection.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: July 5, 2011
    Assignee: The United States of America as respresented by the Department of Health and Human Services
    Inventors: Kathy Hancock, Fatima Williams Whitfield, Melinda L. Yushak, Sowmya Pattabhi, Victor C.W. Tsang
  • XBP1, CD138, AND CS1 PEPTIDES
    Publication number: 20110159021
    Abstract: The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.
    Type: Application
    Filed: June 1, 2009
    Publication date: June 30, 2011
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Nikhil C. Munshi, Kenneth C. Anderson, Jooeun Bae
  • RECOMBINANT NDV ANTIGEN AND USES THEREOF
    Publication number: 20110162115
    Abstract: The present invention encompasses NDV vaccines. The vaccine may be a subunit vaccine based on HN of NDV. The NDV HN may be expressed in plants or algae including microalgae. The invention also encompasses recombinant vectors encoding and expressing NDV antigens, epitopes or immunogens which can be used to protect animals against NDV. It encompasses also a vaccination regime compatible with the DIVA strategy, including a prime-boost scheme using viral vector or inactivated vaccines and subunit vaccines.
    Type: Application
    Filed: December 28, 2010
    Publication date: June 30, 2011
    Inventors: Xuan Guo, Karolyn Marie Troupe, Bradley J. Feilmeier, Joyee A. Pritchard, Julio Sergio Cruz-Coy
  • SELECTION METHOD II
    Publication number: 20110162114
    Abstract: The invention relates to a method for producing a transformed plant cell. More particularly, the method involves the transformation of a plant cell with a Transformation Cassette which is targeted to plant plastids and which comprises a selection gene, for example isopentenyl transferase (IPT), and a transgene. After selection for transformed plastids, expression of a recombinase is induced in the plant cell, which leads to the excision of the selection gene from the plastid and the expression of the transgene in the plastid. The invention also provides cells and plants comprising the Transformation Cassette.
    Type: Application
    Filed: June 12, 2009
    Publication date: June 30, 2011
    Inventors: Simon Geir Moller, Nam-Hai Chua, Jodi Maple
  • Nucleic acids encoding recombinant 56 and 82 kDa antigens from gametocytes of and their uses
    Patent number: 7968695
    Abstract: The present invention provides the recombinant cloning and sequencing of two of the major Eimeria maxima gametocyte antigens having molecular weights of 56 and 82 kDa and the expression of these recombinant antigens in an E. coli expression system using the plasmid pTrcHis. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen. The subject invention also provides two 30 kDa proteins and three 14 kDa proteins from Eimeria maxima gametocytes having at the N-terminal end the amino acid sequence described herein. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen and any of the aforementioned proteins.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: June 28, 2011
    Assignee: Abic Biological Laboratories Ltd.
    Inventors: Sabina I. Belli, Nicholas C. Smith, Michael Wallach
  • Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules
    Publication number: 20110150849
    Abstract: The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
    Type: Application
    Filed: November 19, 2007
    Publication date: June 23, 2011
    Applicant: Immatics Biotechnologies GmbH
    Inventor: Jorn Dengjel
  • Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
    Patent number: 7964374
    Abstract: The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into said new insertion site as medicine or vaccine.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: June 21, 2011
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Howley, Sonja Leyrer
  • Bacillus anthracis antigens, vaccine compositions, and related methods
    Publication number: 20110142870
    Abstract: The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by Bacillus anthracis. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.
    Type: Application
    Filed: February 13, 2007
    Publication date: June 16, 2011
    Inventors: Vidadi Yusibov, Vadim Mett, Konstantin Musiychuck, Marina Skarjinskaia
  • MAMMALIAN CYTOKINES; RELATED REAGENTS
    Publication number: 20110136172
    Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Application
    Filed: February 10, 2011
    Publication date: June 9, 2011
    Applicant: SCHERING CORPORATION
    Inventors: JACQUELINE C. TIMANS, STEFAN KARL-HEINZ PFLANZ, ROBERT A. KASTELEIN, J. FERNANDO BAZAN, DONNA RENNICK, RENE DE WAAL MALEFYT, JEANNE CHEUNG